Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

CERO

CERo Therapeutics Holdings Inc.

Apr 26 • 04:00PM ET

1.37

Dollar change -0.04
Percentage change -2.84	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.38	Insider Own	53.21%	Shs Outstand	14.72M	Perf Week	-8.67%
Market Cap	20.17M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	6.89M	Perf Month	-15.95%
Income	-2.52M	PEG	-	EPS next Q	-	Inst Own	5.67%	Short Float	0.39%	Perf Quarter	-87.59%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	6.46%	Short Ratio	0.02	Perf Half Y	-87.33%
Book/sh	-0.92	P/B	-	EPS next Y	-	ROA	-9.89%	Short Interest	0.03M	Perf Year	-86.42%
Cash/sh	0.58	P/C	2.36	EPS next 5Y	-	ROE	-3.03%	52W Range	1.33 - 12.80	Perf YTD	-87.55%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-89.30%	Beta	-0.07
Dividend TTM	-	Quick Ratio	1.65	Sales past 5Y	0.00%	Gross Margin	-	52W Low	3.01%	ATR (14)	0.35
Dividend Ex-Date	-	Current Ratio	1.65	EPS Y/Y TTM	-572.16%	Oper. Margin	0.00%	RSI (14)	35.13	Volatility	7.99% 17.90%
Employees	9	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-16.75%	Payout	-	Rel Volume	0.07	Prev Close	1.41
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	1.11M	Price	1.37
SMA20	-26.42%	SMA50	-45.12%	SMA200	-84.13%	Trades		Volume	74,663	Change	-2.84%

Mar-07-24 07:00AM	CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients (Business Wire) +20.78%
Feb-14-24 04:48PM	Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination (Business Wire)
Jun-05-23 08:00AM	CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Advancing the Development of Next Generation Engineered T Cell Therapeutics (Business Wire)

CERo Therapeutics Holdings, Inc. is a blank check company, formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded on June 8, 2021 and is headquartered in Oakland, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CERO

CERo Therapeutics Holdings Inc.

Upgrade your FINVIZ experience